Home » USA Broker Ratings » Hologic, Inc. – Consenus Indicates Potential 5.3% Upside

Hologic, Inc. – Consenus Indicates Potential 5.3% Upside

Hologic, Inc. found using ticker (HOLX) now have 16 analysts in total covering the stock. The consensus rating is ‘Buy’. The range between the high target price and low target price is between 60 and 45 calculating the average target price we see 53.02. Now with the previous closing price of 50.33 this indicates there is a potential upside of 5.3%. The 50 day MA is 48.77 and the 200 moving average now moves to 46.83. The company has a market capitalisation of $13,125m. Company Website: http://www.hologic.com

Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.